A5101675236- Migraine and Headache Studies
- Cardiovascular Syncope and Autonomic Disorders
- Epilepsy research and treatment
- Blood Pressure and Hypertension Studies
- Sympathectomy and Hyperhidrosis Treatments
- Multiple and Secondary Primary Cancers
- Trigeminal Neuralgia and Treatments
- Colorectal and Anal Carcinomas
- Multiple Myeloma Research and Treatments
- Infant Development and Preterm Care
- Pharmacological Effects and Toxicity Studies
- Chronic Lymphocytic Leukemia Research
- Gastroesophageal reflux and treatments
- Olfactory and Sensory Function Studies
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Anesthesia and Sedative Agents
- Mesenchymal stem cell research
- Maternal Mental Health During Pregnancy and Postpartum
- Nausea and vomiting management
- Colorectal Cancer Treatments and Studies
- Clinical Laboratory Practices and Quality Control
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Eosinophilic Disorders and Syndromes
- Healthcare Technology and Patient Monitoring
The University of Texas Health Science Center at Houston
2017-2024
The University of Texas MD Anderson Cancer Center
2022-2024
Mays Cancer Center at UT Health San Antonio
2022-2024
AbbVie (United States)
2021-2023
AbbVie (Japan)
2021-2022
University of Bristol
2020-2022
The University of Texas Health Science Center at San Antonio
2016-2022
Brigham Young University
2022
Crabtree (United States)
2022
Alrafidain University College
2022
To evaluate the long-term safety and tolerability of ubrogepant for acute treatment migraine.Ubrogepant is an oral, calcitonin gene-related receptor antagonist in development migraine. The efficacy was demonstrated 2 phase 3 trials which a significant improvement observed migraine headache pain, migraine-associated symptoms, ability to function.This 3, multicenter, randomized, open-label, 52-week extension trial. Adults with or without aura entered trial after completing one lead-in were...
Current emergency care systems are not optimized to respond multiple and complex problems associated with frailty. Services may require reconfiguration effectively deliver comprehensive frailty care, yet its prevalence variation poorly understood. This study primarily determined the of among older people attending care.
Abstract Objective To evaluate the impact of two calcitonin gene–related peptide (CGRP)‐targeted monoclonal antibodies (mAbs), erenumab and galcanezumab, on pharmacokinetic (PK) profile, safety, tolerability ubrogepant. Background People taking CGRP‐targeted mAbs for migraine prevention sometimes take ubrogepant, an oral small‐molecule CGRP receptor antagonist, acute treatment breakthrough attacks. Design In this two‐arm, multicenter, open‐label, phase 1b trial, adults with were randomized...
Abstract Atogepant is a selective oral calcitonin gene‐related peptide receptor antagonist in development for migraine prevention. Here, we report the pharmacokinetics (PK) and safety of single‐dose 60 mg atogepant participants with severe, moderate, or mild hepatic impairment matched normal function from an open‐label, parallel‐group, phase 1 trial. Thirty‐two aged 45 to 72 years were enrolled, which included 8 each mild, no impairment. All completed study. was rapidly absorbed (median time...
Non-contact photoplethysmography (PPG) provides multiple benefits over in-contact methods, but is not as tolerant to motion due the lack of mechanical coupling between subject and sensor. One limitation non-contact discussed here, specifically looking at topology optical variations skin how this impacts upon ability extract a photoplethysmogram when moves horizontally across field view detector (a panning motion). When occurs it shown that whilst general relationships speed traversal,...
Background Ubrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine. This trial evaluated safety and tolerability ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing to healthy participants. Methods In this phase 1, multicenter, double-blind, parallel-group trial, adults (age 18–50 years) were randomized 1:1 placebo or ubrogepant. was dosed at 100 mg (2 × 50...
Atogepant is a selective, oral calcitonin gene-related peptide receptor antagonist in development for preventive treatment of migraine. This randomized, double-blind, phase 1 crossover study evaluated the cardiac repolarization effect single supratherapeutic (300 mg) atogepant dose vs placebo healthy adults. Moxifloxacin 400 mg was open-label active control. The primary end point change from baseline Fridericia-corrected QT intervals (ΔQTcF). Sixty participants were randomized to 300 mg,...
Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist in development for preventive treatment of migraine. To evaluate potential pharmacokinetic drug–drug interactions (DDIs), safety and tolerability atogepant co-administered with acetaminophen or naproxen healthy participants. This open-label, randomized, five-way crossover, single-center, phase 1 DDI trial randomized adult participants to one ten intervention sequences receive single-dose 60 mg atogepant, 1000...
Aim: To evaluate pharmacokinetic interactions of atogepant with sumatriptan, an open-label, randomized, crossover study was conducted. Patients & methods: Thirty healthy adults received 60 mg, sumatriptan 100 or coadministered drugs. Primary end point geometric mean ratios (GMRs) and 90% CIs interventions for area under the plasma concentration–time curve from time 0 to t (AUC0-t) infinity (AUC0-∞) peak concentration (Cmax). Results: Atogepant GMRs AUC0-t AUC0-∞ versus were within CI...
Objective To evaluate the potential for pharmacokinetic interaction and safety tolerability when ubrogepant sumatriptan are coadministered in a Phase 1 study healthy participants, to inform of alone combination with triptans 3 trials participants migraine. Background Calcitonin gene–related peptide is potent vasodilatory neurotransmitter believed play key role pathophysiology Ubrogepant (UBRELVY™) selective antagonist human calcitonin receptor approved acute treatment Sumatriptan serotonin...
Background A novel medical device has been developed to address an unmet need of standardizing and facilitating heart rate recording during neonatal resuscitation. In a time-critical emergency resuscitation, where failure can mean death infant, it is vital that clinicians are provided with information in timely, precise, clear manner capacitate appropriate decision making. This new technology provides hands-free, wireless monitoring solution easily fits the clinical pathway procedure for...
Ubrogepant is a novel, oral calcitonin gene-related peptide receptor antagonist currently under US Food and Drug Administration (FDA) review for the acute treatment of migraine attacks. This double-blind, four-period crossover study compared cardiac repolarization effect therapeutic (100 mg) supratherapeutic (400 ubrogepant doses vs. placebo in healthy adults. Moxifloxacin 400 mg was used as an open-label active control, primary end point change from baseline Fridericia-corrected QT...
Social and structural barriers drive disparities in prenatal care utilization among minoritized women the United States. This study examined impact of Arizona's Health Start Program, a community health worker (CHW) home visiting intervention, on an ethno-racially geographically diverse cohort women.We used administrative state birth certificate data to identify enrolled program during 2006-2016 (n = 7,117). Propensity score matching was generate statistically-similar comparison group 53,213)...
Background: Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist approved by the US Food and Drug Administration for acute treatment of migraine with or without aura in adults. Objectives: To assess potential pharmacokinetic (PK) drug–drug interactions healthy participants inform safety tolerability ubrogepant alone combination acetaminophen nonsteroidal anti-inflammatory drugs (NSAIDs) migraine. Methods: Two phase 1, three-way crossover studies randomized adults...
Ubrogepant is a calcitonin gene-related peptide receptor antagonist indicated for acute treatment of migraine that can be used to treat breakthrough attacks in individuals taking preventive migraine. We evaluated the impact medication use on efficacy and safety ubrogepant This was an analysis pooled data from ACHIEVE I II phase 3 trials, which assessed at 2 h after study pain freedom, absence most bothersome symptom (MBS), relief. In addition, long-term (LTS) extension trial completed where...
Aim: To investigate potential pharmacokinetic interactions between atogepant and esomeprazole. Methods: Atogepant, esomeprazole, or both were administered to 32 healthy adults in an open-label, nonrandomized, crossover study. Systemic exposure (area under the plasma concentration–time curve [AUC] peak concentration [Cmax]) for combination versus alone compared using a linear mixed effects model. Results: Coadministration with esomeprazole delayed time Cmax by ∼1.5 h reduced ∼23% no...
Survival of patients with multiple myeloma (MM) has improved as a result therapeutic advances. There is evidence that some MM develop pulmonary hypertension (PH). The objective this study was to identify risk factors echocardiographic PH and its impact on outcomes MM.We conducted retrospective (N = 359) diagnosed between 2000 2011 within the Geisinger Medical Center. Chart review subgroup who underwent transthoracic echocardiogram 2 years being having MM.A total 34% 123/359) 32% 39/123) had...